Skip to Content

Bioasis Technologies Inc BIOAF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological disease and disorders. The company has worked on blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier. Its source of revenue involves the research and license revenue.

Contact
14 Water Street, P.O. Box 64
Guilford, CT, 06437, Canada
T +1 203 533-7082
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Nov 30, 2020
Fiscal Year End Feb 28, 2020
Stock Type
Employees